Company / Operating Income
Cogent Biosciences, Inc. Operating Income History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$333.4M
FY2025
5-year range
-$333.4M / -$75.6M
FY2021-FY2025
Trend
-20.8%
vs FY2024
Sector context
#169 of 204
Health Care
What the data says
Cogent Biosciences, Inc.'s operating income of -$333M is lower than 83% of companies in the Health Care sector (FY2025). Operating Income has declined for 4 consecutive years, from -$76M in FY2021 to -$333M in FY2025.
Based on SEC 10-K filings.
-$333M in FY2025.
Declined from -$208M to -$333M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 204This company -$333.4M Sector average $107.7M
▼
-409.5% below sector average
Key checks
Key Insights
- Cogent Biosciences, Inc.'s operating income has declined for 4 consecutive years.
- In FY2025, operating income decreased 20.8% year-over-year.
- Ranks #169 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$333.4M | -20.8% |
| FY2024 | -$275.9M | -32.6% |
| FY2023 | -$208.1M | -40.8% |
| FY2022 | -$147.8M | -95.7% |
| FY2021 | -$75.6M | +8.1% |
| FY2020 | -$82.2M | -155.5% |
| FY2019 | -$32.2M | +10.6% |
| FY2018 | -$36.0M | -37.7% |
| FY2017 | -$26.2M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026